Q2 EPS Forecast for Oramed Pharmaceuticals Raised by Analyst

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Investment analysts at Zacks Research lifted their Q2 2026 EPS estimates for Oramed Pharmaceuticals in a research note issued on Thursday, June 18th. Zacks Research analyst M. Marin now expects that the biotechnology company will post earnings of $0.43 per share for the quarter, up from their previous forecast of $0.15. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is $0.71 per share. Zacks Research also issued estimates for Oramed Pharmaceuticals’ Q3 2026 earnings at $0.52 EPS and Q4 2026 earnings at $0.46 EPS.

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Oramed Pharmaceuticals Trading Up 4.0%

Shares of ORMP opened at $4.17 on Wednesday. The firm has a market cap of $170.68 million, a PE ratio of 1.61 and a beta of 1.26. The firm has a fifty day simple moving average of $3.98 and a two-hundred day simple moving average of $3.54. Oramed Pharmaceuticals has a 1-year low of $1.98 and a 1-year high of $5.01.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings data on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ORMP. SB Capital Management Inc purchased a new stake in Oramed Pharmaceuticals during the fourth quarter valued at approximately $5,415,000. Marshall Wace LLP bought a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at $738,000. Dimensional Fund Advisors LP grew its position in shares of Oramed Pharmaceuticals by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after acquiring an additional 7,738 shares during the period. Ritholtz Wealth Management bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $529,000. Finally, Bank of America Corp DE increased its stake in shares of Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after purchasing an additional 6,261 shares in the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.